This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Venetoclax will be administered orally.
Other Name: ABT-199
Other Name: GDC-0199
- The participant must not be eligible for a venetoclax clinical trial.
- Pediatric participants may be evaluated on a case by case basis.
ABBVIE CALL CENTER